ATE486285T1 - Verfahren zur früherkennung von krebs - Google Patents

Verfahren zur früherkennung von krebs

Info

Publication number
ATE486285T1
ATE486285T1 AT07706065T AT07706065T ATE486285T1 AT E486285 T1 ATE486285 T1 AT E486285T1 AT 07706065 T AT07706065 T AT 07706065T AT 07706065 T AT07706065 T AT 07706065T AT E486285 T1 ATE486285 T1 AT E486285T1
Authority
AT
Austria
Prior art keywords
cancer
determining
kits
subject
methods
Prior art date
Application number
AT07706065T
Other languages
English (en)
Inventor
Nadir Arber
Original Assignee
Medical Res Fund Of Tel Aviv S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Fund Of Tel Aviv S filed Critical Medical Res Fund Of Tel Aviv S
Application granted granted Critical
Publication of ATE486285T1 publication Critical patent/ATE486285T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT07706065T 2006-01-31 2007-01-31 Verfahren zur früherkennung von krebs ATE486285T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76337806P 2006-01-31 2006-01-31
PCT/IL2007/000122 WO2007088537A2 (en) 2006-01-31 2007-01-31 Methods and kits for early detection of cancer or predisposition thereto

Publications (1)

Publication Number Publication Date
ATE486285T1 true ATE486285T1 (de) 2010-11-15

Family

ID=38001788

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07706065T ATE486285T1 (de) 2006-01-31 2007-01-31 Verfahren zur früherkennung von krebs

Country Status (12)

Country Link
US (1) US9394569B2 (de)
EP (1) EP1994410B1 (de)
JP (1) JP5091163B2 (de)
AT (1) ATE486285T1 (de)
DE (1) DE602007010108D1 (de)
DK (1) DK1994410T3 (de)
ES (1) ES2355388T3 (de)
IL (1) IL193097A (de)
PL (1) PL1994410T3 (de)
PT (1) PT1994410E (de)
SI (1) SI1994410T1 (de)
WO (1) WO2007088537A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007010108D1 (de) 2006-01-31 2010-12-09 Medical Res Fund Of Tel Aviv S
EP2220505B1 (de) * 2007-12-10 2015-10-28 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Krebsdiagnoseverfahren
WO2010062706A2 (en) * 2008-10-30 2010-06-03 Caris Mpi, Inc. Methods for assessing rna patterns
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
EP2524059A4 (de) 2010-01-13 2013-11-20 Caris Life Sciences Luxembourg Holdings Detektion von gastrointestinalen erkrankungen
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
US10267800B2 (en) 2010-05-21 2019-04-23 The Governors Of The University Of Alberta Methods for the assessment of colorectal cancer and colorectal polyps by measurement of metabolites in urine
EP3052651B1 (de) 2013-10-01 2019-11-27 Life Technologies Corporation Systeme und verfahren zum nachweis von strukturvarianten
ES2939298T3 (es) 2017-05-21 2023-04-20 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct Combinación de marcadores para el diagnóstico del cáncer
US20200408761A1 (en) * 2018-02-28 2020-12-31 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods of diagnosing and treating bladder cancer
EP4369356A2 (de) 2018-11-30 2024-05-15 Caris MPI, Inc. Molekulare profilierung der nächsten generation
CN110777213A (zh) * 2019-11-05 2020-02-11 武汉科技大学 一种潜伏期胃癌诊断试剂盒
JP2023504270A (ja) 2019-12-02 2023-02-02 カリス エムピーアイ インコーポレイテッド 汎がんのプラチナ反応予測子
US11840720B2 (en) 2019-12-23 2023-12-12 Metabolomic Technologies Inc. Urinary metabolomic biomarkers for detecting colorectal cancer and polyps

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2101943A1 (en) * 1991-02-05 1992-08-06 Kamal Bahar Simple test for detecting carcinoembryonic antigen
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US7081516B2 (en) * 2002-08-26 2006-07-25 Case Western Reserve University Methods for categorizing patients
CA2479724A1 (en) * 2002-03-19 2003-10-02 Tularik Inc. Gene amplification in cancer
US20040097448A1 (en) * 2002-11-19 2004-05-20 Isis Pharmaceuticals Inc. Modulation of CD24 expression
WO2005024603A2 (en) * 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
WO2005054810A2 (en) * 2003-11-26 2005-06-16 The Ohio State University Research Foundation Polymorphic cd24 genotypes that are predictive of multiple sclerosis risk and progression
CA2453198A1 (en) 2004-01-07 2005-07-07 Wei-Ping Min Quantification and generation of immune suppressive exosomes
JP4912894B2 (ja) * 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
DE602007010108D1 (de) 2006-01-31 2010-12-09 Medical Res Fund Of Tel Aviv S

Also Published As

Publication number Publication date
ES2355388T3 (es) 2011-03-25
WO2007088537A2 (en) 2007-08-09
DK1994410T3 (da) 2011-01-31
EP1994410A2 (de) 2008-11-26
PL1994410T3 (pl) 2011-12-30
SI1994410T1 (sl) 2011-03-31
US20100062450A1 (en) 2010-03-11
JP2009525041A (ja) 2009-07-09
DE602007010108D1 (de) 2010-12-09
IL193097A0 (en) 2009-02-11
IL193097A (en) 2013-03-24
JP5091163B2 (ja) 2012-12-05
WO2007088537A3 (en) 2007-10-25
US9394569B2 (en) 2016-07-19
EP1994410B1 (de) 2010-10-27
PT1994410E (pt) 2011-01-10

Similar Documents

Publication Publication Date Title
ATE486285T1 (de) Verfahren zur früherkennung von krebs
BRPI0607508A2 (pt) métodos e ácidos nucléicos para análise de distúrbios proliferativos celulares
WO2010005991A3 (en) Circulating tumor and tumor stem cell detection using genomic specific probes
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2013022995A3 (en) Biomarker compositions and methods
WO2007089911A3 (en) Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
WO2010019550A3 (en) Method of identifying disease risk factors
ATE522627T1 (de) Verfahren zur herstellung von nukleinsäuresonden
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
RU2013146242A (ru) Fgfr и его лиганды в качестве биомаркеров рака молочной железы у hr-положительных индивидуумов
TW200643175A (en) Markers for prenatal diagnosis and monitoring
WO2009047756A3 (en) Methods and kits for diagnosing lung cancer
MX2009005651A (es) Marcadores geneticos para el manejo de riesgo de la arritmia cardiaca.
WO2006002243A3 (en) Methods of oligosaccharide profiling for the detection of cancer
EA200970695A1 (ru) Способы и нуклеиновые кислоты для анализов нарушений клеточной пролиферации
WO2008140463A3 (en) Biomarker panels for assessing radiation injury and exposure
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
HK1133295A1 (en) Use of protein s100a12 as a marker for colorectal cancer s100a12
WO2006026074A3 (en) Atherosclerotic phenotype determinative genes and methods for using the same
WO2005112568A3 (en) Haplotype markers and methods of using the same to determine response to treatment
WO2010020619A3 (en) Susceptibility to dasatinib
WO2014023808A3 (en) Method for evaluating a cancer patient for propensity to respond to a therapy
ATE486964T1 (de) Molekulares verfahren zur diagnose von prostatakrebs
ATE408712T1 (de) Verfahren zur bestimmung des wiederauftretens von prostata krebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1994410

Country of ref document: EP